Recent News

• 03.19.2026 - Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
• 03.19.2026 - Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
• 02.17.2026 - Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 12.02.2025 - Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
• 11.24.2025 - Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
• 11.20.2025 - Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.06.2025 - Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
• 08.21.2025 - Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
• 08.21.2025 - Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investor Conference
• 08.14.2025 - Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 03.19.2026 - EX-99.1 EX-99.1
• 03.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.21.2025 - EX-99.1 EX-99.1
• 08.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.14.2025 - EX-99.1 EX-99.1